Expert Opinion on Drug Delivery, Год журнала: 2025, Номер unknown

Опубликована: Июнь 2, 2025

Hyaluronic acid (HA) has been widely explored in cancer drug delivery due to its biocompatibility, biodegradability and excellent cargo properties. Recently, HA-based formulations have gained renewed interest thanks the HA involvement many CD44-overexpressing tumors, offering potential for active targeting, tumor microenvironment modulation, immune response regulation. This review explores role of receptor progression as a strategy therapeutic targeting. It also outlines current status clinical therapy, emphasizing their outcomes. The use HA-drug conjugates, -decorated nanoparticles (NPs), chemotherapy, gene theranostics is reviewed. Additionally, recent advancements system modulation are discussed. All presented systems herein evaluated ability selectively target cells, with focus on vivo biodistribution efficacy. Despite significant research, few technologies progressed trials, only one showing promising results. Key challenges include high production costs, industrial scale-up feasibility, need preserve recognition, off-target accumulation liver spleen barriers that must be addressed successful translation.

Язык: Английский